AngioDynamics (NASDAQ:ANGO) Upgraded to “Buy” at Wall Street Zen

AngioDynamics (NASDAQ:ANGO) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Friday.

A number of other equities analysts have also recently issued reports on ANGO. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Canaccord Genuity Group increased their price target on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Price Performance

AngioDynamics stock opened at $12.60 on Friday. AngioDynamics has a 12 month low of $6.91 and a 12 month high of $13.50. The company has a fifty day moving average price of $11.73 and a two-hundred day moving average price of $10.43. The company has a market cap of $518.91 million, a PE ratio of -16.15 and a beta of 0.74.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The company had revenue of $75.71 million for the quarter, compared to analysts’ expectations of $72.69 million. During the same period in the prior year, the company earned ($0.11) earnings per share. The firm’s revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Equities research analysts anticipate that AngioDynamics will post -0.37 earnings per share for the current year.

Insider Activity at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the transaction, the chief executive officer owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction that occurred on Tuesday, October 21st. The stock was acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the transaction, the senior vice president owned 93,597 shares in the company, valued at $1,105,380.57. This trade represents a 11.96% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 20,890 shares of company stock valued at $239,532. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently modified their holdings of ANGO. State of Alaska Department of Revenue acquired a new stake in AngioDynamics in the third quarter worth about $25,000. Washington Trust Advisors Inc. bought a new stake in shares of AngioDynamics during the 3rd quarter worth about $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics in the 2nd quarter worth approximately $31,000. Russell Investments Group Ltd. lifted its stake in shares of AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 4,268 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.